DelveInsight’s, “Hemophilia A Pipeline Insights 2026” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in the Hemophilia A pipeline landscape. It covers the Hemophilia A pipeline drug
DelveInsight’s “Diabetic Neuropathy Market Insights, Epidemiology, and Market Forecast – 2036” report delivers an in-depth understanding, historical and forecasted epidemiology, as well as the Diabetic Neuropathy market trends in the
A patient receives an advanced exosome facial in Severna Park, MD, as part of the specialized non-surgical aesthetic treatments at Optimal Longevity MD. Optimal Longevity MD introduces its advanced exosome
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Type 1 Diabetes pipeline constitutes 85+ key companies continuously working towards developing 100+ Type 1 Diabetes treatment therapies, analysis of
The Key Psoriasis Companies in the market include – UCB Pharma, Novartis, Sun Pharmaceutical/ Almirall, Bausch Health, Boehringer Ingelheim, LEO Pharma, AnaptysBio, Nimbus Lakshmi/Takeda, MoonLake Immunotherapeutics, Can-Fite Biopharma, E-nitiate Biopharmaceuticals,
The Key Peanut Allergy Companies in the market include – Stallergenes Greer, Roche and Novartis, DBV Technologies, Novartis, ALK-Abello, Aravax, InnoUp Farma, Intrommune Therapeutics, and others. DelveInsight’s “Peanut Allergy
The Key Allergic Rhinitis Companies in the market include – Regeneron Pharmaceuticals, Allergy Therapeutics, Inmunotek, UCB Pharma, Orexo AB, Hyloris Pharmaceuticals, Revelation Biosciences Inc., Yingu Pharmaceutical, Glenmark Specialty S.A., Pfizer,
The Claudin 18.2 Directed Therapies Market is poised for significant growth, driven by the increasing adoption of biomarker-driven oncology treatments, rising prevalence of gastric and pancreatic cancers, expanding use of
The Aortic Aneurysm Stent Grafts Market is witnessing significant growth owing to the increasing burden of vascular diseases, rising geriatric population, growing preference for minimally invasive aneurysm repair procedures, and
Leading Metastatic Prostate Cancer Therapies include Apalutamide (ERLEADA), Enzalutamide (XTANDI), Darolutamide (NUBEQA), Cabazitaxel (JEVTANA), Abiraterone acetate (ZYTIGA), Lutetium vipivotide tetraxetan (PLUVICTO), Olaparib (LYNPARZA), Talazoparib (TALZENNA), TLX591, Mevrometostat (PF-06821497), Cabozantinib (CABOMETYX),
